BlackRock
SGMT icon

BlackRock’s Sagimet Biosciences SGMT Stock Holding History

BlackRock’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.18M Sell
799,943
-14,010
-2% -$78.1K ﹤0.01% 3898
2025
Q4 		$4.82M Buy
813,953
+201,236
+33% +$1.45M ﹤0.01% 3851
2025
Q3 		$4.2M Buy
612,717
+129,634
+27% +$1.05M ﹤0.01% 3846
2025
Q2 		$3.68M Sell
483,083
-487,741
-50% -$2.06M ﹤0.01% 3888
2025
Q1 		$3.16M Sell
970,824
-7,899
-0.8% -$33.1K ﹤0.01% 3831
2024
Q4 		$4.4M Buy
978,723
+26,132
+3% +$132K ﹤0.01% 3776
2024
Q3 		$2.64M Buy
952,591
+48,508
+5% +$150K ﹤0.01% 3915
2024
Q2 		$3.09M Sell
904,083
-1,121,528
-55% -$5.14M ﹤0.01% 3850
2024
Q1 		$11M Buy
2,025,611
+1,638,210
+423% +$11.8M ﹤0.01% 3305
2023
Q4 		$2.1M Buy
387,401
+63,993
+20% +$302K ﹤0.01% 4022
2023
Q3 		$2.85M Buy
+323,408
New +$4.31M ﹤0.01% 3877

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock's SGMT Position: Q1 2026 in Review

BlackRock reduced its Sagimet Biosciences (SGMT) stake by 1.7% in Q1 2026, selling an estimated $78.1K and leaving 799,943 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3898.

BlackRock first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $11M in Q1 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • BlackRock held 799,943 shares of Sagimet Biosciences worth $4.18M as of Q1 2026.
  • BlackRock sold 14,010 Sagimet Biosciences shares in Q1 2026, an estimated $78.1K.
  • Sagimet Biosciences made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3898 holding.
  • BlackRock first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • BlackRock's Sagimet Biosciences position peaked at $11M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.